<DOC>
	<DOCNO>NCT01460160</DOCNO>
	<brief_summary>The purpose study determine whether Dasatinib add standard chemotherapy effective safe treatment pediatric philadelphia chromosome positive acute lymphoblastic leukemia</brief_summary>
	<brief_title>Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Newly diagnose Philadelphia chromosome positive Acute Lymphoblastic Leukemia ( ALL ) Age &gt; 1 year &lt; less 18 year old Induction chemotherapy â‰¤ 14 day accord institutional standard care Adequate liver , renal cardiac function Prior treatment Oncogene fusion protein ( BCRABL ) inhibitor Extramedullary involvement testicle Active systemic bacterial , fungal viral infection Down syndrome</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>